Custom GLP Peptides Manufacturers & Pricelist

Semaglutide comprises a 31-amino-acid backbone with a non-standard alpha-aminoisobutyric acid (Aib) at position 8 and an elaborate side-chain at Lys26 (composed of a mono-tert-butyl-protected C18 diacid, two 8-amino-3,6-dioxaoctanoic acid [AEEA] spacers, and an L-glutamic acid alpha-tert-butyl ester). Key challenges include: (1) Steric resistance during coupling at and adjacent to the sterically congested Aib residue, which often necessitates microwave-assisted heating or specialized coupling cocktails (e.g., Oxyma/DIC or HATU); (2) Intra-chain beta-sheet aggregation during solid-phase elongation, mitigated by incorporating pseudoproline dipeptides (such as Fmoc-Gly-Thr(ψMe,Mepro)-OH); and (3) Maintaining orthogonal protection on Lys26 (typically Lys(Alloc) or Lys(Mmt)) to execute side-chain acylation while the peptide remains on resin without prematurely cleaving acid-sensitive side chains.

During standard Fmoc SPPS, the cleavage of the synthesized peptide from the solid resin and the global deprotection of amino acid side chains require high concentrations of trifluoroacetic acid (TFA, typically 90%–95%). Consequently, the crude peptide precipitates as a trifluoroacetate salt. While acceptable in preliminary research (RUO), TFA is biologically problematic in parenterals due to potential cellular toxicity, histological injection-site intolerance, and adverse impacts on finished drug product pH buffering and long-term stability. Commercial cGMP standards require conversion to acetate or chloride salts via anion-exchange resins or dynamic column chromatography, reducing residual TFA levels to strictly ≤ 0.10% (w/w).

Impurity control requires high-resolution orthogonal analytical techniques. Deletion sequences (N-1, N-2) generated by incomplete deprotection or coupling are isolated via high-performance reversed-phase liquid chromatography (RP-HPLC) using superficially porous core-shell or sub-2μm C18 columns coupled to Orbitrap or Q-TOF Mass Spectrometers. Diastereomeric impurities—caused by amino acid racemization during repeated activation cycles (notably prone in His, Cys, and Ser residues)—exhibit identical mass to the target molecule and can only be separated using specialized shallow mobile-phase gradients (water/acetonitrile with ammonium acetate or perchlorate modifiers) and enantioselective chiral amino acid analysis (Chiral-AAA) following total acid hydrolysis.

Commercial and clinical-grade API campaigns include comprehensive regulatory dossiers: (1) Full Certificate of Analysis (CoA) documenting HPLC purity, single largest impurity, Net Peptide Content, elemental assay, residual solvents via Headspace GC, residual counter-ions (TFA/Acetate), Karl Fischer water titration, bioburden, and bacterial endotoxin levels; (2) Detailed batch release records and synthesis flowcharts; (3) Structural elucidation packages comprising high-resolution accurate mass spectrometry (HRMS), tandem MS/MS sequencing, 1D/2D 1H- and 13C-NMR spectroscopy, and amino acid composition analysis; (4) Open Part of the Drug Master File (DMF) with Letters of Authorization (LOA); and (5) Real-time and accelerated stability study data generated according to ICH Q1A(R2) protocols.

Both platforms operate commercially, but chemical synthesis provides distinct strategic benefits for modified analogues: (1) Chemical SPPS easily incorporates non-canonical and D-amino acids (such as Aib in Semaglutide or unnatural amino acid building blocks in Tirzepatide and Retatrutide), whereas recombinant expression systems (e.g., E. coli or yeast) are restricted to the 20 natural amino acids without complex amber codon expansion machinery; (2) Post-translational chemical acylation of recombinant precursor proteins requires multi-step in vitro enzymatic cleavage, enzymatic purification, and chemical conjugation, introducing significant downstream yield losses; and (3) Multi-ton automated chemical peptide reactors provide faster campaign changeovers and lower capital facility investment barriers compared to large-scale fermentation suites.

Bulk lyophilized peptide APIs are sealed in high-density polyethylene (HDPE) pharmaceutical-grade containers with dual medical-grade poly-bags and pharmaceutical desiccant pouches under an inert nitrogen blanket to prevent moisture absorption and subsequent deamidation. Global distribution is executed using temperature-validated dry ice packaging (-20°C or -80°C) equipped with real-time GPS and NIST-calibrated electronic data-loggers that record temperature, humidity, and shock conditions continuously throughout transport until final receiving-dock receipt and QA clearance.